For over 25 years, the Slater Heelis team has been highly regarded as a leading provider of legal services in the North West of England for the life sciences industry.
We work closely with ambitious businesses to navigate legal and regulatory requirements at each stage of their development. Whether your focus is biomedical research, drug discovery and development, diagnostics software or product marketing, we are here to support your company objectives with expert advice that is only a telephone call away.
No matter how complex the challenges you are facing, our life sciences solicitors have been there before and understand how to maximise opportunities and mitigate risks before they arise. Our legal expertise covers all aspects of life sciences law – from acquisitions and disposals, to licensing, regulatory advice, intellectual property and financing.
We take a vested interest in the goals and growth of our clients’ businesses and help them to thrive in the market space in which they operate. This approach allows us to form lasting client relationships that are critical to long-term success.
Exceptional client service at every turn
Slater Heelis’ approach to client service is what sets us apart from other law firms – we are clear in advice, transparent over cost and seek to add value for our clients wherever possible.
We take pride in maintaining a diverse client base, which includes regional and national businesses of all sizes, in both public and private sectors. This approach gives us a far broader understanding of the sector and the bespoke requirements of our clients.
As Head of our Life Sciences department, Simon Wallwork brings over two decades of industry experience to the team. Simon is known for his proactive, commercial approach and is frequently recognised as a leading solicitor within both Chambers and Legal 500 directories.
What our clients say about us…
“Slater Heelis has been, and continues to be, a real asset to Blueberry. They are a key member of the extended Blueberry Therapeutics team, helping to shape our corporate strategy and move the company forward. Their most notable recent impact was assistance in closing our first significant financing round earlier this year.”
John Ridden, CEO of Blueberry Therapeutics